Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Cash from Financing Activities (2017 - 2025)

Historic Cash from Financing Activities for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to $5.7 million.

  • Protagonist Therapeutics' Cash from Financing Activities fell 5304.12% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.1 million, marking a year-over-year increase of 764.69%. This contributed to the annual value of $25.9 million for FY2024, which is 8483.49% down from last year.
  • Latest data reveals that Protagonist Therapeutics reported Cash from Financing Activities of $5.7 million as of Q3 2025, which was down 5304.12% from $2.9 million recorded in Q2 2025.
  • Protagonist Therapeutics' 5-year Cash from Financing Activities high stood at $125.4 million for Q2 2021, and its period low was $527000.0 during Q4 2023.
  • For the 5-year period, Protagonist Therapeutics' Cash from Financing Activities averaged around $19.2 million, with its median value being $4.0 million (2024).
  • Per our database at Business Quant, Protagonist Therapeutics' Cash from Financing Activities crashed by 9945.77% in 2022 and then surged by 1580764.71% in 2023.
  • Over the past 5 years, Protagonist Therapeutics' Cash from Financing Activities (Quarter) stood at $2.2 million in 2021, then tumbled by 74.55% to $553000.0 in 2022, then decreased by 4.7% to $527000.0 in 2023, then skyrocketed by 664.9% to $4.0 million in 2024, then surged by 40.39% to $5.7 million in 2025.
  • Its Cash from Financing Activities stands at $5.7 million for Q3 2025, versus $2.9 million for Q2 2025 and $11.4 million for Q1 2025.